Insider Purchases: Inside the Buy

Tag: Speculative Plays

Bezuclastinib vial on biotech lab bench, with clinical trial data and stock chart rising in background—symbolizing COGT’s potential breakthrough

July 15, 2025

Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib

Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥

Read entire article

A flat-style cartoon illustration of two Repay executives holding oversized receipts labeled

May 18, 2025

Repay Holdings: Time to Reward the Patient Holder?

Insider buying is heating up at Repay Holdings. With over 200 institutions on board and a bargain-bin valuation, this fintech underdog might be getting ready to repay patient investors—with upside.

Read entire article

Tags: CEO insider buying, Cheap Stocks, digital payments, fintech, Funanc1al, Funanc1al for Investors, Funanc1al Investing, Funanc1alInvesting, Growth Investing, insider buying, Institutional Ownership, Repay Holdings, RPAY, Small Cap, Speculative Plays, Stock Market Humor, Turnaround Stocks, Value Investing

Your cart

Insider Purchases: Inside the Buy

Tag: Speculative Plays

July 15, 2025

Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib

May 18, 2025

Repay Holdings: Time to Reward the Patient Holder?

Quick links

Contact us

About us

Follow us